Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

6-1-2022

Network assisted analysis of de novo variants using proteinprotein interaction information identified 46 candidate genes for
congenital heart disease
Yuhan Xie
Yale University

Wei Jiang
Yale University

Weilai Dong
Yale University

Hongyu Li
Yale University

Sheng Chih Jin
Washington University School of Medicine in St. Louis

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Xie, Yuhan; Jiang, Wei; Dong, Weilai; Li, Hongyu; Jin, Sheng Chih; Brueckner, Martina; and Zhao, Hongyu,
"Network assisted analysis of de novo variants using protein-protein interaction information identified 46
candidate genes for congenital heart disease." PLoS Genetics. 18, 6. e1010252 (2022).
https://digitalcommons.wustl.edu/oa_4/63

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Yuhan Xie, Wei Jiang, Weilai Dong, Hongyu Li, Sheng Chih Jin, Martina Brueckner, and Hongyu Zhao

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/63

PLOS GENETICS
RESEARCH ARTICLE

Network assisted analysis of de novo variants
using protein-protein interaction information
identified 46 candidate genes for congenital
heart disease
Yuhan Xie ID1, Wei Jiang ID1, Weilai Dong ID2, Hongyu Li ID1, Sheng Chih Jin3,
Martina Brueckner2,4, Hongyu Zhao ID1,2,5*

a1111111111
a1111111111
a1111111111
a1111111111
a1111111111

1 Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, United States of
America, 2 Department of Genetics, Yale School of Medicine, New Haven, Connecticut, United States of
America, 3 Department of Genetics, Washington University School of Medicine, St Louis, Missouri, United
States of America, 4 Department of Pediatrics, Yale University, New Haven, Connecticut, United States of
America, 5 Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut,
United States of America
* hongyu.zhao@yale.edu

OPEN ACCESS
Citation: Xie Y, Jiang W, Dong W, Li H, Jin SC,
Brueckner M, et al. (2022) Network assisted
analysis of de novo variants using protein-protein
interaction information identified 46 candidate
genes for congenital heart disease. PLoS Genet
18(6): e1010252. https://doi.org/10.1371/journal.
pgen.1010252
Editor: Xiaofeng Zhu, Case Western Reserve
University, UNITED STATES
Received: December 13, 2021
Accepted: May 12, 2022
Published: June 7, 2022
Copyright: © 2022 Xie et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: Summary statistics
of real data application can be downloaded from
https://github.com/JustinaXie/NDATA. Results of
simulation and real data can be downloaded from
S1 Table and S2 Table in the Supporting
Information.
Funding: This work was supported in part by NIH
grant R03HD100883-01A1 (Y.X. and H.Z.) and
R01GM134005-01A1 (W.J., H.L., and H.Z.). The
funders had no role in study design, data collection

Abstract
De novo variants (DNVs) with deleterious effects have proved informative in identifying risk
genes for early-onset diseases such as congenital heart disease (CHD). A number of statistical methods have been proposed for family-based studies or case/control studies to identify risk genes by screening genes with more DNVs than expected by chance in Whole
Exome Sequencing (WES) studies. However, the statistical power is still limited for cohorts
with thousands of subjects. Under the hypothesis that connected genes in protein-protein
interaction (PPI) networks are more likely to share similar disease association status, we
developed a Markov Random Field model that can leverage information from publicly available PPI databases to increase power in identifying risk genes. We identified 46 candidate
genes with at least 1 DNV in the CHD study cohort, including 18 known human CHD genes
and 35 highly expressed genes in mouse developing heart. Our results may shed new
insight on the shared protein functionality among risk genes for CHD.

Author summary
The topologic information in a pathway may be informative to identify functionally interrelated genes and help improve statistical power in DNV studies. Under the hypothesis
that connected genes in PPI networks are more likely to share similar disease association
status, we developed a novel statistical model that can leverage information from publicly
available PPI databases. Through simulation studies under multiple settings, we proved
our method can increase statistical power in identifying additional risk genes compared to
methods without using the PPI network information. We then applied our method to a
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real example for CHD DNV data, and then visualized the subnetwork of candidate genes
to find potential functional gene clusters for CHD.

Introduction
Congenital heart disease (CHD) is the most common birth defect affecting ~ 1% of live births
and accounts for one-third of all major congenital abnormalities [1–3]. There is substantial
evidence that CHD has a strong genetic component [4]. Although it is estimated that aneuploidies and copy number variations account for about 23% of CHD cases, few individual diseasecausing genes have been identified in published studies [5–8]. Therefore, the limited knowledge of the underlying genetic causes poses an obstacle to the reproductive counseling of CHD
patients [9].
Whole Exome Sequencing (WES) studies have successfully boosted novel causal gene identification for both Mendelian and complex disorders [10,11]. To narrow down the pool of candidate variants from WES, family-based studies have been conducted to scan for de novo
variants (DNVs) from parent-offspring trios. DNV studies have been shown to play an important role in risk gene identification for CHD [1,3,5,6,12–15]. From the analysis of 1,213 CHD
parent-offspring trios, Homsy et al. identified a greater burden of damaging DNVs, especially
in genes with likely functional roles in heart and brain development [12]. Recently, Jin et al.
inferred that DNVs in ~440 genes were likely contributors to CHD [5]. Despite these advances,
it remains challenging to capture the causal genes with only DNV data as CHD is very genetically heterogeneous [6].
Several statistical methods have been proposed to identify risk genes by integrating DNVs
with other genetic variants and additional biological data. He et al. developed a Bayesian
framework, namely the Transmission And De novo Association (TADA), to increase statistical
power of inferring risk genes by incorporating both DNMs and rare inherited variants [16]. A
hierarchical Bayes strategy was adopted for parameter estimation in TADA. Following this
idea, a number of methods have been proposed to improve TADA, with some focusing on
leveraging the shared genetic information in multiple correlated phenotypes, such as neurodevelopmental disorders and CHD [17,18], whereas others extend the method by integrating
DNMs with other types of genetic variants and functional annotations [19–22]. Please note
that, except for DECO [22], all these methods treat each gene individually and do not consider
the interaction effects of genes. Thus, there is a pressing need for developing network-based
frameworks to consider the functional connectivities among genes.
Network-based approaches have been successful in prioritizing risk genes for downstream
genomic and transcriptomic studies [23–26]. Chen et al. [24] proposed a Markov Random
Field (MRF) model to incorporate pathway topology structure for Genome-Wide Association
Studies (GWAS). They showed that their method is more powerful than single gene-based
methods through both simulation and real data analyses. In 2015, Liu et al. adopted a similar
idea as Chen et al. to analyze DNV data from WES studies [27]. Their framework, namely
DAWN, combines TADA p-values with the estimated network from gene co-expression data.
In their real data analysis for autism, 333 genes were prioritized by integrating DNV summary
statistics and expression data from brain tissue. However, the above methods require summary
statistics (Z scores or p-values) from genetic association analysis as their input, which may not
be provided from results of DNV analysis [17,19].
More recently, Bayrak et al. developed a priority score to quantify the proximity of genes to
the known CHD risk genes using DNV data [3]. Utilizing canonical pathways and human
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gene networks, their analyses identified 23 novel genes that are likely to contribute to CHD
pathogenesis. Their results further support the potential to improve power by integrating network information with DNV data. Then, the question becomes how to choose an informative
gene network for CHD. As there is a limited number of co-expression data sets for human
developmental heart, a natural choice for network information would be human PPI databases. There are multiple primary PPI network databases such as BioGRID [28], IntAct [29],
DIP [30], MINT [31], and HPRD [32]. Most network-based studies apply their real data on
two or more of databases to obtain their results. Nonetheless, it is hard to check the overlapping information between two PPI databases and interpret the divergent results. Multiple integrative databases such as STRING [33], HINT [34], UniHI [35], hPRINT [36] and GPS-Prot
[37] provide a platform to resolve the above problems [38]. Among them, STRING is a popular
PPI resource that imports protein association knowledge from physical interaction and
curated knowledge from the primary PPI databases and other pathway information knowledge
such as KEGG [39–41] and GO [42,43]. In addition, it provides a score to measure the likelihood of interactions. Some studies have used STRING in their post-association analysis for
gene-based DNV studies and showed significant enrichment of candidate CHD risk genes in
the STRING PPI network [44,45]. These results suggest that incorporating PPI network information from STRING may identify additional risk genes with more biological interpretability.
As an illustrative example, we applied TADA de novo test [16] with the CHD DNV data
curated in our previous work [18], and conducted a post-association analysis on the p-values
returned from the test. After false discovery rate (FDR) adjustment of p-values, we identified
21 genes with FDR<0.1 among 18,856 genes tested, and found that the number of edges
formed by the 21 genes (20 edges, blue line in Fig 1A) is much larger than the upper tail of the
empirical distribution sampled from 21 randomly selected genes in the STRING V11.0 database (score threshold: 400) for 10,000 times (Fig 1A). This suggests that the candidate CHD
genes are highly enriched in terms of their interactions in the STRING database. To further
illustrate that PPI information may contribute to CHD gene discovery, we showed the number
of edges formed by the top genes ranked by adjusted p-values for CHD and compared it with

Fig 1. CHD top genes are more connected than randomly selected genes in the STRING PPI network. (A) Empirical distribution of the number of edges
formed by 21 randomly selected genes. Blue line represents the number of edges formed by the 21 CHD top genes from TADA de novo analysis. (B) Blue line
represents the number of edges formed by CHD top genes and red line represents randomly selected genes.
https://doi.org/10.1371/journal.pgen.1010252.g001
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the number of edges formed by randomly selected genes with a more stringent selection of PPI
edges in the STRING database (score threshold: 950) in Fig 1B. We considered 95th percentile
of the empirical distribution derived from 10,000 sets of random genes in the PPI network as a
baseline. When more than 20 top CHD genes are selected, the number of edges formed by
these genes is significantly more than that from randomly selected genes. This suggests top
genes in CHD tend to be neighbors in the STRING PPI network.
Motivated by the observation from Fig 1, we develop a Network assisted model for De novo
Association Test using protein-protein interAction information, named N-DATA, to leverage
prior information of interactions among genes from the PPI network to boost statistical power
in identifying risk genes for CHD based on the ‘guilt by association’ principle [46, 47]. In the
following, we first introduce the inference procedure for our model, and then demonstrate the
performance of our method through simulation studies and real data applications.

Methods
In this section, we introduce the statistical model for the proposed framework. The network
information in the PPI database is represented by an undirected graph G = (V,E), where V =
{1,..,n} is a set of n genes in the network, and E = {<i,j>: i and j are genes connected by the
edges}. The degree of a gene i is defined as the number of direct neighbors (Ni) for gene i in
the network and denoted as di. We denote the latent association status of gene i with a disease
of interest, e.g., CHD, as Si, where Si = 1 if gene i is associated with the disease, Si = −1 if gene i
is not associated with the disease. S = {S1,..,Sn} are the corresponding latent states for genes in
V = {1,. . .,n}. The DNV count of each gene i is defined as Yi. We propose a simple discrete
Markov random field model [48, 49] with a nearest neighbor Gibbs measure [50] to model the
following joint probability function S = {S1,..,Sn}:
� X
�
X
X
PðSjy0 Þ / exp h
I1 ðSi Þ þ t0
ðwi þ wj ÞI 1 ðSi ÞI 1 ðSj Þ þ t1
ðwi þ wj ÞI1 ðSi ÞI1 ðSj Þ ;
i2V

<i;j>2E

<i;j>2E

where wi is the weight for gene i and will be chosen based on the characteristics of the network.
In real data analysis, we set wi as the square root of the degree of gene i in the network
pffiffiffi
(wi ¼ di ) following Chen et al. [24]. θ0 = (h, τ0, τ1) are hyperparameters related to the network. Specifically, h determines the marginal distribution of Si when all genes are independent
expðhÞ
i.e., PðSi ¼ 1jh; t0 ¼ t1 ¼ 0Þ ¼ 1þexpðhÞ
. τ0 and τ1 characterize the prior weights of edges
between non-associated genes and associated genes, respectively. We further assume that,
given the latent state Si, the DNV count Yi follows a Poisson distribution. The mutability of
gene i (μi) can be estimated using the framework in Samocha et al. [12, 51]. Based on the derivation in TADA [16], the probability of observing DNVs for gene i in each trio can be approximated by 2μiγ, where γ is the relative risk of the DNVs. Further, the expected count of DNVs
for gene i in N trios is 2Nμiγ. When gene i is not a risk gene, γ is equal to 1. Then, we have the
following model for DNV counts:
Yi jSi ¼

1 � Poissonð2Nmi Þ;

Yi jSi ¼ 1 � Poissonð2Nmi gÞ;
y0 ¼ ðh; t0 ; t1 Þ; y1 ¼ g:
To reduce the computational burden from a fully Bayesian solution for maximizing the
marginal likelihood, we propose an empirical Bayes method to estimate the parameters θ0 and
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θ1, and the latent association status S by maximizing the pseudo conditional likelihood
(PCLK) for n genes as follows
n
Y

PCLK ¼

fðYi jSi ; y1 ÞPrðSi jSNi ; y0 Þ;
i¼1

where SNi represents the latent association status for neighbors of gene i. It has been shown
that the estimator from the PCLK in a general Markov random field setting is consistent under
mild regularity conditions [24,49]. When maximizing the PCLK, we can estimate the hyperparameters θ0, θ1 and latent status S iteratively.
Qn
We can obtain an empirical estimate for θ0 by maximizing i¼1 PrðSi jSNi ; y0 Þ, which is
equivalent to maximizing the parameters in the following logistic regression model:
logit PrðSi jSNi ; y0 Þ ¼ h þ t1 Xi1

t0 Xi0 ;

P
P
where Xi1 ¼ wi k2Ni I1 ðSk Þ þ k2Ni wk I1 ðSk Þ and
P
P
Xi0 ¼ wi k2Ni I 1 ðSk Þ þ k2Ni wk I 1 ðSk Þ; i ¼ 1; . . . ; n. To make sure the estimated θ0 is finite,
we can add a ridge penalty term lðh2 þ t20 þ t21 Þ to the likelihood function to solve the maximization problem by the Newton-Raphson’s method [52].
We then update the latent status S by maximizing the PCLK using the iterative conditional
mode method [49]. After we obtain the updated values θ0 and S, we can estimate the hyperQn
parameter θ0 by maximizing i¼1 f ðYi jSi ; y1 Þ by using the following closed-form expression:
Y
log Lðy1 jYÞ / log
expð 2mNg þ Yi loggÞ
Si ¼1

@log Lðy1 jYÞ
¼
@g

P

X

Si ¼1

2mN þ

g

Si ¼1

P
^g ¼ P

Si ¼1
Si ¼1

Yi

Yi

2mN

Algorithm 1: Procedure for Parameter Estimation
1. Set initial configuration S0
2. In the jth iteration, for given s(j−1), obtain y^j0 from

logit Pr ðSðji

1Þ

jSðjNi 1Þ ; yðj0

1Þ

Þ ¼ h þ t1 Xi1

t0 Xi0 ; i ¼ 1; � � � ; n

3. Sequentially update the labels of nodes to obtain S(j) (ICM)

^^ðj
SðjÞ
i ¼ arg maxsi f ðYi jSi ; y 1

1Þ

Y
ÞPr ðSi jSðjNi 1Þ ; y^^ðjÞ
Pr ðSðjk
0 Þ
k2S
N

1Þ

jSi ; SðjNk 1Þi ; y^^ðjÞ
0 Þ

4. Obtain y^j1 ð^g ðjÞ Þ from
ðjÞ
ðjÞ
y^1 ¼ argmaxy1 log Lðy1 jyðjÞ
0 ; S ; YÞ

5. Repeat steps 2, 3, and 4 until convergence
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Finally, after we obtain the estimated y^0 and y^1 , we use Gibbs sampling based on the conditional distribution PðS jS ; y^ ; y^ Þ. This method has been proved to be valid for multiple testi

Ni

0

1

ing under dependence in a compound decision theoretic framework [53,54]. Then, we can
estimate the marginal posterior probability qi = P(Si = −1|Y). Let q(i) be the sorted values of qi
in descending order. For each gene i, the null hypothesis and alternative hypothesis are
Hi0 : Gene i is not associated with the trait of interest
Hi1 : Gene i is associated with the trait of interest
As shown by Jiang and Yu [55], the relationship between global FDR and local FDR (lfdr) is
FDR = E(lfdr|Y2R), where the rejection region R is the set of Y such that the null hypothesis
can be rejected based on a specific rejection criterion. To control the expected global FDR less
n
o
Ps
than α, we propose the following procedure: let m ¼ max s : 1s i¼1 qðiÞ , we reject all the
null hypotheses corresponding to H(1),. . .,H(m).

Verification and comparison
We used network information from the STRING PPI database and simulated DNV count data
to study the performance of our method. First, we randomly selected 2,000 genes, retrieved
their mutability from the real data, and extracted the corresponding PPI network formed by
these 2,000 genes. Then, we simulated the latent status of genes with Gibbs sampling under the
given network information, and the count of DNVs for each gene with the Poisson distribution given the latent status of the gene. We evaluated FDR and power under various settings of
sample size N and relative risk parameter γ.
We fixed true network parameter h as -4 and varied τ1 from 0.1 to 0.9 to make the total
number of risk genes in the network of 2,000 random genes vary from 57 to 353. We varied
the sample size N at 2,000, 5,000 and 10,000 to evaluate the performance of N-DATA in small,
medium, and large WES cohorts, respectively. In addition, we varied β (log relative risk parameter γ) at 3, 3.5, and 4 to investigate the performance of N-DATA around the burden estimated
^ = 3.60). Each simulation setting was replicated
results from real data (In real data analysis, b
100 times. For Gibbs sampling-based inference, we used 5,000 MCMC iterations, and set the
first 2,000 iterations as burn-ins. These numbers were chosen empirically based on the diagnostic plots for convergence.
First, we compared the performance of N-DATA model with and without the PPI network
as input. For N-DATA model without the PPI network, we assigned the weight of gene i wi = 0
for inference. We present the power and FDR performance of N-DATA models in Fig A and
Fig B in S1 Text. Then, we compared the power of TADA de novo test (TADA-De novo),
DAWN, and N-DATA using the same simulation settings. Hyperprior of TADA-De novo was
estimated from the function denovo.MOM based on the recommendation from the authors
[16]. Power of TADA was calculated based on TADA p-values under FDR adjustment. DAWN
v1.0 was downloaded from http://www.compgen.pitt.edu/DAWN/DAWN_homepage.htm. We
adapted the code of DAWN by substituting the adjacency matrix inferred from its Partial
Neighborhood Selection algorithm to the adjacency matrix from network. We used TADA-De
novo p-values and PPI network as the input of DAWN. We applied default settings for parameters in DAWN.
We compared the performance of TADA-De novo, TADA-De novo p-values + DAWN and
N-DATA under different simulation settings. We reported the power performance under FDR
threshold 0.05 in the main text (Fig 2). We first checked if all three methods could control the
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Fig 2. Power comparison of TADA-De novo, TADA-De novo p-values + DAWN and N-DATA. Error bars represent standard errors estimated from 100
replications of simulation. Three panels in each sub-figure from left to right represent β = 3, β = 3.5, and β = 4, respectively. Each panel shows the change of
power when τ1 varies from 0.1 to 0.9. (A) Power comparison between the two models when the sample size is small (N = 2,000). (B) Power comparison between
the three models when the sample size is medium (N = 5,000). (C) Power comparison between the three models when the sample size is large (N = 10,000).
https://doi.org/10.1371/journal.pgen.1010252.g002

global FDR when the threshold is 0.05 (Fig C in S1 Text). Overall, N-DATA controlled the
FDR well and had the best power under all scenarios. We observed that when τ1, N, and β are
all small, DAWN had FDR inflations for some runs. We suspect that this may be due to the
discreteness of p-values, resulting in the violation of the normal distribution assumption for
corresponding z-scores used in the input of DAWN. When the number of risk genes is small,
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DAWN may have lower power than TADA and N-DATA. When τ1, N, and β became larger,
the power of DAWN was comparable with N-DATA. Time comparisons for the three models
are presented in Fig D in S1 Text.

Application
We applied N-DATA to DNV data from 2,645 CHD trios reported in Jin et al [5], and annotated the CHD variants by ANNOVAR [56]. We denoted loss of function (LoF) as frameshift
insertion/deletion, splice site alteration, stopgain and stoploss predicted by ANNOVAR, and
deleterious missense (Dmis) predicted by the MetaSVM [57] algorithm. We only consider
damaging variants (LoF and Dmis) in our analysis as the number of non-deleterious variants
is not expected to provide the information to differentiate cases from controls biologically
[58].
For network information, we first downloaded STRING v11.0 with medium edge likelihood
via interface from STRINGdb package in R and call this original network from STRING G 0 .
We obtained the curated list of known human CHD genes from Jin el al [5] and expanded the
gene list by including additional candidate genes (FDR<0.1) from the single-trait analysis in
our previous work [18]. This gene list (258 genes) was set as seed genes for our network. Then,
we extracted the subnetwork including the seed genes and the direct neighbors with likelihood
score larger than 950 of those genes and call this subnetwork G 1 . We only kept overlapping
genes with our DNV data in G1 and called the final network used in our real application as G2 .
There were in total 1,814 genes and 21,468 edges in G2 .
To show that our method can leverage network information to boost risk gene identification, we applied our algorithm without using the network as an input. When there was no
prior information from the network, we identified 18 significant genes with FDR<0.05. To
include the network information from G 2 we denote the degree of gene i in network G2 as di,
pffiffiffi
and let the weight in the prior as wi ¼ di . After adding the network information from G2 , we
identified 46 genes with at least 1 DNV, and 26 genes harboring at least 2 DNVs with
FDR<0.05 in the CHD cohort.
We also compared the results of N-DATA with TADA-De novo test [16]. As in the simulation study, we observed that DAWN may not control the FDR under the preset threshold
under our network and cohort settings. Thus, we did not include the results of DAWN in the
comparison. TADA-De novo test (p-values with FDR adjustment) identified 28 significant
genes. Without integrating the network information, N-DATA can identify 18 significant
genes with FDR<0.05. After integrating the G 2 network, N-DATA identified 323 genes with
FDR<0.05. As some of the genes may be prioritized due to network characteristics, but did
not have DNV count in the study cohort (more details in S1 Text), we further filtered out
genes without DNV and considered the 46 genes identified with FDR<0.05 and at least 1
DNV as the candidate genes. (Table 1)
We visualized the overlap of 258 seed genes, genes that were identified by TADA-De novo
p-values, N-DATA w/o network model, and N-DATA in Fig 3. Fig 3A shows the 323 genes
Table 1. Comparison of TADA and N-DATA models.
Method

Criteria

TADA-De novo p-values

FDR<0.05

Number of Identified Genes
28

N-DATA w/o Network

FDR<0.05

18

N-DATA
(Network G 2 network + DNV counts)

FDR<0.05
DNVs�1

323
46

https://doi.org/10.1371/journal.pgen.1010252.t001
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Fig 3. Venn diagram of 258 seed genes, TADA genes, N-DATA w/o network genes and N-DATA genes. (A) Overlapping genes between 258 seed genes,
TADA genes, N-DATA w/o network (N-DATA Null) genes and 323 N-DATA genes. (B) Overlapping genes between 258 seed genes, TADA genes, N-DATA
w/o network (N-DATA Null) genes and 46 N-DATA candidate genes.
https://doi.org/10.1371/journal.pgen.1010252.g003

identified by N-DATA, while Fig 3B shows the 46 genes with at least 1 DNV. From Fig 3B,
N-DATA found most of the genes that can be identified by TADA (26 out of 28).
Further, we calculated the overlap of the significant genes identified by N-DATA and
TADA, and 872 genes that are highly expressed (top 25%) in mouse developing heart at E14.5
[12] and in the 1,814 gene network (HHE genes) (Fig 4). Among the 323 N-DATA identified
genes, 27 are known human CHD genes and 213 genes are HHE genes. Among the 46 genes,
18 are known human CHD genes and 35 are HHE genes.

Fig 4. Venn diagram of HHE genes, TADA genes, N-DATA w/o network genes, and the N-DATA genes. (A) Overlapping genes between 872 HHE genes,
TADA genes, N-DATA w/o network (N-DATA Null) genes, and 323 N-DATA genes. (B) Overlapping genes between 872 HHE genes, TADA genes, N-DATA
w/o network (N-DATA Null) genes, and 46 N-DATA candidate genes.
https://doi.org/10.1371/journal.pgen.1010252.g004

PLOS Genetics | https://doi.org/10.1371/journal.pgen.1010252 June 7, 2022

9 / 18

PLOS GENETICS

Network assisted analysis of de novo variants

We visualized the 323 genes identified in the G 2 network (S1 Fig). The 323 genes formed
two major clusters. The bigger cluster (right) is an extended cluster for protein synthesis genes,
including ribosome protein genes (RPL-, RPS-), peptide chain elongation genes (EEF-, EIF-,
SPR-, GSPT-), rRNA processing genes (UTP-, WDR-, RIOK-, NO-, IMP-), etc. Though without finding DNVs in the current cohort, ribosome genes RPL11, RPL35A, RPS10, RPS19,
RPS24, RPS26, and RPS7 are known CHD genes. Ribosome dysfunctions have been implicated
in a variety of developmental disorders, including CHD [59]. For instance, multiple genes
encoding ribosome subunits are known to cause Diamond-Blackfan anemia and 30% of the
patients also presented CHD [60]. Functional studies showed that the deficiency in ribosomes
can impact cell growth which might be a potential mechanism to cause CHD [61,62].
The other cluster (left) is the extended cluster for mRNA splicing genes, which encode various components of spliceosome and associated factors, such as snRNP (LSM-, SNRNP-,
SNRP-), pre-mRNA processing factors (PRPF-), RNA helicases (DDX-, DHX-), hnRNPs
(HNRNP-), and splicing factors (SF3-, SRS-, CWC-) [63]. Heart development involves many
alternative splicing events. Mutations in splicing associated factor genes such as RBM24,
RBFOX2 and SF3B1, have been shown to cause cardiac malformation in mouse and human
[64]. A specific type of snRNP called snoRNA and its targets showed reduced expression in
myocardium of infants with Tetralogy of Fallot and impacted heart development through
impairing spliceosome functions [65].
Thus, genes in the two clusters may be associated with CHD via disruption of protein synthesis or mRNA splicing events.
Further, we zoomed in on the 46 genes with at least 1 DNV in the G2 network to demonstrate that the PPI network information can help boost statistical power and provide biological
interpretation for the current CHD cohort. (Fig 5)
Among the 46 candidate genes, PTPN11, RAF1 and RIT1 had 2 recurrent DNVs, and
CHD7, NOTCH1, NSD1 and PYGL also had recessive genotypes in the CHD cohort [5]. The
46 candidate genes form 4 clusters in the G2 network (Fig 5). The biggest cluster includes
seven known CHD genes TBX5, KMT2D, PTPN11, SOS1, ACTB, NOTCH1, and PTEN, which
are involved in transcriptional regulation and early cell growth or differentiation processes.
The six new genes SMAD2, KLF4, CTNNB1, CDC42, ITSN2, and WWTR1 also function in
similar pathways and have varied implications for cardiac development. For instance, KLF4
and CTNNB1 have been implicated in cardiac cell differentiation [66]. Cdc42 cardiomyocyte
knock-out mice presented heart defects such as ventricular septum defects and thin ventricular
walls [67]. WWTR1 encodes a transcription regulator, which serves as an effector of Hippo
pathway and regulates cardiac wall maturation in zebrafish [68].
The second biggest cluster is constituted of 7 new genes, all of which are involved in mRNA
splicing. Specifically, SART1, SRRM2, PRPF38A, PRPF8, and SF3B1 are associated factors or
components of spliceosome; HNRNPK encodes a pre-mRNA-binding protein; DHX9 encodes
an RNA helicase which promotes R-loop formation while RNA splicing is perturbed [69].
Alternative splicing plays an essential role in heart development, homeostasis, and disease
pathogenesis. Mouse knockouts of multiple splice factors had impaired cardiogenesis [70].
SF3B1, specifically, has been shown to upregulate to induce heart disease in both human and
mice [64]. Thus, though not fully investigated, DNVs in those mRNA splicing-related genes
may contribute to CHD pathogenesis.
The third cluster contains genes involved in protein synthesis, including the known gene
RPL5 and genes not previously associated with CHD (EIF4, EIF5, EEF2, and RPL10). RPL5
and RPL10 encode the ribosome subunits. Mutations in RPL5 and other ribosomal genes can
lead to multiple congenital anomalies, including CHD [71]. EIF4 and EIF5 encode translation
initiation factors while EEF2 encodes the elongation factor that regulate peptide chain
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Fig 5. N-DATA model identified 46 candidate genes with at least 1 DNV. Green labels indicate the 18 genes
identified when no network information was provided for N-DATA, and red labels indicate the additional 28 genes
identified when the G 2 network was integrated. Circles indicate the 18 known human CHD genes, and squares indicate
the 28 novel genes identified by N-DATA.
https://doi.org/10.1371/journal.pgen.1010252.g005

elongation during protein synthesis. A recent study reported that the deficiency in ribosome
associated NatA complex reduces ribosomal protein and subsequently impact cell development as a mechanism to cause CHD [62]. Thus, DNVs in the above genes may lead to CHD
via impairment of protein synthesis.
The last cluster contains the known CHD genes BRAF and RAF1, both of which encode key
kinases in Ras signaling and are related to Noonan syndrome with CHD as a common feature.
Among the un-clustered genes, six are identified after using the network information:
ABCE1, UBE2B, SDC1, PYGL, KDM5B, MED20. UBE2B and KDM5B, encoding epigenetic
modifiers, have shown suggestive evidence in cardiac development or CHD [72,73] and might
be potential CHD genes.

Discussion
In this article, we have introduced a Bayesian framework to integrate PPI network information
as the prior knowledge into DNV analysis for CHD. The implemented model is available at
https://github.com/JustinaXie/NDATA. This approach adopts MRF to model the interactions
among genes. We apply an empirical Bayes strategy to estimate parameters in the model and
conduct statistical inference based on the posterior distribution sampled from a Gibbs
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sampler. The simulation studies and real data analysis on CHD suggest that the proposed
method has improved power to identify risk genes over methods without integrating network
information.
Our proposed framework is innovative in the following aspects. First, it does not need to
estimate hyperprior based on other sources compared to the existing pathway-based test for
DNV data [22,45]. Second, it does not require external expression data for the DNV cohort
and uses the publicly available PPI database instead, which makes it more applicable to different diseases. This method not only increases power in risk gene identification, but also assists
in biological interpretation by visualizing clusters of risk genes with functional relevance in the
network.
However, there are some limitations in the current N-DATA model. First, our model is
dependent on the choice of network. Using different PPI networks and different filtering criteria could result in a different set of significant genes. Currently, we did not provide a way to
prioritize existing networks. We have provided details on a comparison of using the HINT network versus the STRING network (more details in S1 Text). For the two networks compared
in our study, HINT has the advantage of leveraging additional information from PDB [74],
and being manually curated to filter out erroneous and low-quality interactions; while
STRING has the advantage of providing a score to measure the likelihood of interactions, and
including information from multiple pathway databases. We also found that the risk genes
identified from the two databases had a significant overlap (p = 3.14×10−12). The overlapping
risk genes were highly enriched for Human Phenotype Ontology (HPO) [75] terms related to
CHD from g:Profiler [76] analysis, and p-values of overlapped pathway outputs from Ingenuity Pathways Analysis (IPA, QIAGEN Inc.) had a significant Pearson’s correlation (R = 0.48;
p<2.2×10−16).
Second, our model may be only used for early on-set disorders with a strong DNV signal.
For diseases with small relative risks or small sample sizes, our model may suffer from convergency issues (more details in S1 Text). In real applications, it is important to conduct an initial
analysis on the enrichment of top genes identified from de novo association tests in the network like our motivating example.
Third, we applied an empirical Bayes strategy to obtain point estimates of hyperparameters
instead of using a fully Bayesian approach considering the computation burden. A fully Bayesian model that can account for intrinsic uncertainties would be a potential future direction.
Fourth, likelihood-based inference may suffer from local maxima [24]. Although we didn’t
identify significant differences of different initiation points from our simulation study (more
details in S1 Text), we recommend initiating the labels of genes from a known risk gene set or
running with multiple starts for real data application (more details in S1 Text). Also, we
observe the Gibbs sampler tends to move around local maxima for some time before convergence. Empirically, we suggest running at least 2,000 times of iterations and discarding the
first 1,000 iterations as burn-ins. Fifth, we only considered the simulation verification under
the ground truth model based on our assumptions, the generalizability to other alternative
models is unexplored.
Sixth, to apply our model to other diseases, practitioners should be cautious if they would
like to use the mutability of genes from a public dataset. 1) For WES data, the target region for
each study could be different, which further results in differences in the calculation of mutability for the coding region 2) Mutability may be calculated based on a specific functional annotation of variants. Studies that use divergent classification criteria for variants should not share
the same mutability. 3) Publicly available mutability may have been adjusted for cohort-specific parameters, such as sequencing depth, which may also affect the results if adapted to
another cohort.
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In addition, we only considered damaging DNVs and assumed the relative risk parameter γ
is the same across all genes in N-DATA, which may cause our model to lose power if it varies
across variants with different functions (e.g., LoF and Dmis). Future studies may explore adding functional annotation of variants as a layer in the model to further improve statistical
power.
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